Likewise, in contrast to the studies outlined above, OS and DFS rates were significantly shorter with 5 year OS at 54% versus 72%, and 5 year DFS at 39% versus 61%, for AR-positive versus AR-negative cancers respectively, echoing the results of an earlier Polish study [65,66]. The gene discussed is AR; the disease is cancer.